The effects of Donepezil on traumatic brain injury acute rehabilitation outcomes

Brain Inj. 2004 Aug;18(8):739-50. doi: 10.1080/02699050310001646224.

Abstract

Primary objective: To evaluate the effects of administering Donepezil during inpatient rehabilitation for individuals with TBI.

Research design: Retrospective, age and injury severity matched, mixed between-within subjects analysis.

Methods and procedures: Thirty-six patients with moderate-to-severe TBI admitted to acute rehabilitation within 90 days of injury. Main outcome measures included FIM cognitive total scores and rehabilitation lengths of stay.

Intervention: Initiation of Donepezil administration beginning at 5 mg daily. Dose titration and continuation based on perceived clinical response.

Main outcomes and results: No differences in cognitive improvement were observed between the Donepezil treatment group and the matched control group. Sub-set analyses suggested that administration of Donepezil early in the rehabilitation stay was significantly related to higher rates of cognitive improvement.

Conclusions: Preliminary evidence suggests that Donepezil administration early in the rehabilitation stay may have advantageous treatment effects. A prospective, randomized, placebo-controlled clinical trial with standard timing, dosage and treatment duration is recommended to further evaluate treatment efficacy.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Adult
  • Analysis of Variance
  • Brain Injuries / drug therapy*
  • Brain Injuries / psychology
  • Brain Injuries / rehabilitation
  • Cognition Disorders / drug therapy*
  • Cognition Disorders / etiology
  • Donepezil
  • Drug Administration Schedule
  • Female
  • Humans
  • Indans / therapeutic use*
  • Length of Stay
  • Male
  • Middle Aged
  • Neuropsychological Tests
  • Nootropic Agents / therapeutic use*
  • Piperidines / therapeutic use*
  • Rehabilitation Centers
  • Retrospective Studies
  • Treatment Outcome

Substances

  • Indans
  • Nootropic Agents
  • Piperidines
  • Donepezil